FOLD - CONSENSUS CO - Amicus Therapeutics

Amicus Therapeutics (FOLD) is a recognized expert in the therapy of orphan diseases, developing breakthrough treatments for critically ill patients. The company generates revenue from the sale of patented medications for Fabry disease and other genetic disorders. Effective partnerships with external manufacturers ensure supply stability. This price chart illustrates the asset's current price action, where a key indicator stands at .

Portfolio managers highly value the cash flow stability of Amicus Therapeutics (FOLD), driven by lifelong treatment for orphan diseases. This indicator represents the weighted average target price of the shares, calculated based on current professional analyst models. By analyzing the history of expert consensus estimates, an investor can see the trend of the asset's fundamental value. However, a sharp rise in rates could adjust these forecasts. The regularity of sales confirms the business's resilience.